MedTrace Logo

Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)

NCT04329975 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1087

Last updated 2024-12-20

No results posted yet for this study

Summary

To investigate the incidence and risk factors of desmopressin-induced hyponatremia during long-term treatment (1 year \[52 weeks\]) of MINIRINMELT orally disintegrating (OD) tablets 25μg/50μg (drug) for nocturia caused by nocturnal polyuria in men in daily clinical practice, and to confirm the compliance with proper use of this drug in clinical practice and to investigate the effectiveness of risk minimization activities.

Conditions

  • Nocturia Due to Nocturnal Polyuria

Interventions

DRUG

Desmopressin

Desmopressin (MINIRINMELT OD tablet) 25μg or 50μg, orally.

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Global Clinical Compliance · Ferring Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-19
Primary Completion
2024-09-25
Completion
2024-09-25

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04329975 on ClinicalTrials.gov